Thyroid Surgery Center, West China Hospital of Sichuan University, Chengdu, 610041, China.
Laboratory of Thyroid and Parathyroid Disease, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, 610041, Sichuan, China.
Endocrine. 2022 Dec;78(3):436-440. doi: 10.1007/s12020-022-03129-1. Epub 2022 Jul 25.
The novel coronavirus disease 2019 (COVID-19) produced by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly contagious infectious disease. In addition to typical flu-like symptoms, COVID-19 can also cause extrapulmonary spread and systemic inflammation, potentially causing multiorgan dysfunction, including thyroid dysfunction. Thyroid function changes in patients with COVID-19 have been widely reported, but the results are inconsistent. Based on available data, SARS-CoV-2 infection can lead to changes in thyroid function, and the degree of thyroid function changes was positively correlated with the severity of COVID-19, which involved multiple potential mechanisms. In contrast, current evidence was insufficient to prove that thyroid function changes could induce the progression of COVID-19 clinical deterioration.
由严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)引起的 2019 年新型冠状病毒病(COVID-19)是一种高度传染性的传染病。除了典型的流感样症状外,COVID-19 还可能引起肺外传播和全身炎症,可能导致多器官功能障碍,包括甲状腺功能障碍。COVID-19 患者的甲状腺功能变化已被广泛报道,但结果不一致。基于现有数据,SARS-CoV-2 感染可导致甲状腺功能改变,甲状腺功能改变的程度与 COVID-19 的严重程度呈正相关,涉及多个潜在机制。相比之下,目前的证据还不足以证明甲状腺功能改变会导致 COVID-19 临床恶化的进展。